You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Covaxin rolled out in Bengal, 60 beneficiaries to be inoculated on Day 1

The West Bengal health department on Wednesday rolled out Covaxin, developed by Bharat Biotech, at three vaccination centres in the city

Coronavirus | Coronavirus Vaccine

Press Trust of India  |  Kolkata 

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma

The West Bengal health

department on Wednesday rolled out Covaxin, developed by Bharat Biotech, at three vaccination centres in the city -- each set to inoculate 20 frontline COVID-19 warriors during the day -- an official said.

The three centres -- state-run SSKM hospital, RG Kar Medical College and Hospital and Kolkata Medical College and Hospital - would be administering the vaccines to health and civic workers, after they sign a consent form.

"Everyone receiving Covaxin doses are required to sign an informed consent form. Today, a total of 60 beneficiaries at the three sites will be administered this vaccine. We do not want to take any chance. Slowly and slowly, we will speed up the process," the official told.

So far, Covishield, manufactured by Pune-based Serum Institute of India, has been administered to nearly three lakh people in Bengal.

Among those who received Covaxin on the first day are National Health Mission managing director Saumitra Mohan, its programme officer Smita Sanyal Sukla and Directorate of Medical Education head Dr Debasish Bhattacharya.

A second consignment of Covaxin vaccines reached the city from Hyderabad earlier in the day, the official added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, February 03 2021. 14:12 IST